Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A1 | P43005 | 2/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.47 |
| ▸ | IDO1 | P14902 | 2/20 | 0.46 |
| ▸ | AGXT | P21549 | 2/20 | 0.46 |
| ▸ | PPARG | P37231 | 2/20 | 0.43 |
| ▸ | PPARA | Q07869 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | MIF | P14174 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4422549 | 1.00 | SLC1A1 (0.50) | SLC1A1TAAR1IDO1AGXTPPARG | |
| SCHEMBL2427588 | 1.00 | SLC1A1 (0.50) | SLC1A1TAAR1IDO1AGXTPPARG | |
| SCHEMBL8499668 | 0.86 | SLC1A1 (0.49) | SLC1A1TAAR1IDO1AGXTPPARG | |
| SCHEMBL2965194 | 0.85 | PNMT (0.47) | TAAR1PPARGCYP2D6CYP2C9ALOX15 | |
| SCHEMBL8499664 | 0.85 | SLC1A1 (0.47) | SLC1A1TAAR1IDO1AGXTPPARG | |
| SCHEMBL6224951 | 0.83 | SLC1A1 (0.53) | SLC1A1TAAR1IDO1AGXTPPARG | |
| SCHEMBL2623871 | 0.83 | TAAR1 (0.50) | SLC1A1TAAR1IDO1AGXTCYP2D6 | |
| SCHEMBL10586409 | 0.82 | SLC1A1 (0.49) | SLC1A1TAAR1IDO1AGXTPPARG | |
| SCHEMBL15178111 | 0.82 | SLC1A1 (0.49) | SLC1A1TAAR1IDO1AGXTPPARG | |
| SCHEMBL3122648 | 0.82 | ANPEP (0.46) | SLC1A1TAAR1IDO1AGXTPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2319919-B1 | Nitrilases | BASF ENZYMES LLC (US) | 2015-08-12 | — | — | EP | disclosed |
| EP-2115153-B1 | NITRILASES, NUCLEIC ACIDS ENCODING THEM AND METHODS FOR MAKING AND USING THEM | BP CORP NORTH AMERICA INC (US) | 2013-06-05 | — | — | EP | disclosed |
| EP-2327767-A1 | Nitrilases | Verenium Corporation (US) | 2011-06-01 | — | — | EP | disclosed |
| EP-2327765-A1 | Nitrilases | Verenium Corporation (US) | 2011-06-01 | — | — | EP | disclosed |
| EP-2319919-A1 | Nitrilases | Verenium Corporation (US) | 2011-05-11 | — | — | EP | disclosed |
| US-20100273659-A1 | Nitrilases, Nucleic Acids Encoding Them and Methods for Making and Using Them | VERENIUM CORPORATION (US) | 2010-10-28 | — | — | US | disclosed |
| EP-1463506-B1 | SUBSTITUTED QUINAZOLINE DERIVATIVES AS INHIBITORS OF AURORA KINASES | ASTRAZENECA AB (SE) | 2009-10-21 | — | — | EP | disclosed |
| EP-2039762-A2 | Nitralases | Verenium Corporation (US) | 2009-03-25 | — | — | EP | disclosed |
| WO-2008106662-A2 | NITRILASES, NUCLEIC ACIDS ENCODING THEM AND METHODS FOR MAKING AND USING THEM | VERENIUM CORPORATION (US) | 2008-09-04 | — | — | WO | disclosed |
| US-20070078168-A1 | PYRIDINE CARBOXYLIC ACID DERIVATIVES AS GLUCOKINASE MODULATORS | ASTRAZENECA AB (SE) | 2007-04-05 | — | — | US | disclosed |
| US-20070078168-A1 | PYRIDINE CARBOXYLIC ACID DERIVATIVES AS GLUCOKINASE MODULATORS | ASTRAZENECA AB (SE) | 2007-04-05 | — | — | US | disclosed |
| WO-2005044801-A1 | PYRIDINE CARBOXYLIC ACID DERIVATIVES AS GLUCOKINASE MODULATORS | ASTRAZENECA AB (SE) | 2005-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078168-A1 | PYRIDINE CARBOXYLIC ACID DERIVATIVES AS GLUCOKINASE MODULATORS | GCK, GCKR, GALK1 | SLC1A1 658/4885TAAR1 3335/4885IDO1 3225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.